1996

Established Zhejiang Aoxing Biotechnology Co., Ltd.

2004

Establishment of Jiangsu Aoxin Biological Engineering Co., Ltd.

Pharmaceutical raw materials industry ushered in new development opportunities, performance differentiation in the growth potential.

In the ever-changing territory of the pharmaceutical industry, API, as a key link in the industrial chain, its performance has always affected the nerves of the market.

Frontier Exploration of Pharmaceutical Raw Material Industry: Deep Integration of Biotechnology and Digital Transformation

With the rapid development of biotechnology and the deepening of digital transformation, the pharmaceutical raw material industry is undergoing changes.

Future Outlook of Pharmaceutical Raw Material Industry: Green, Intelligent and Globalization

Driven by the dual drive of biotechnology and digital transformation, the pharmaceutical raw material industry is gradually moving towards a new era of green, intelligent and globalization.

2024 API midfield battle report: positive growth of less than 40%, "move back" under the tide of how to transform?

In the ever-changing territory of the pharmaceutical industry, API, as a key link in the industrial chain, its performance has always affected the nerves of the market.

Return to the high growth of raw materials pharmaceutical companies dividend period is coming

The integrated pharmaceutical companies of raw materials and preparations, represented by Huahai Pharmaceuticals and Sinopharm Hyundai, achieved high growth in the first three quarters of 2024, which mainly benefited from the recovery of the business climate of raw materials, as well as the continuous reduction of cost efficiency, management and preparation integration dividends.

Pharmaceutical sector three-quarter performance differentiation API and biological products performance ahead.

A few days ago, the National Bureau of Statistics announced the performance of China's economy in the first three quarters, and the pharmaceutical manufacturing industry grew by 3.1 in the first three quarters.